Byoung Cho

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Pharmacokinetics and bioavailability of pembrolizumab with berahyaluronidase alfa for subcutaneous administration in participants with advanced or metastatic solid tumors: The phase 1 study 3475A-C18.

Pharmacokinetics and bioavailability of pembrolizumab with berahyaluronidase alfa for subcutaneous administration in participants with advanced or metastatic solid tumors: The phase 1 study 3475A-C18.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 14, 2025

Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation.

Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 27, 2024

Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities.

Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 15, 2024

Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study.

Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 22, 2023

Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations.

Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 15, 2023

Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201.

Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 07, 2023

Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial.

Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 18, 2023

Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.

Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 06, 2023

Identification of Local Clusters of Mutation Hotspots in Cancer-Related Genes and Their Biological Relevance.

Identification of Local Clusters of Mutation Hotspots in Cancer-Related Genes and Their Biological Relevance.

Journal: IEEE/ACM transactions on computational biology and bioinformatics

Published: July 12, 2018

Showing 1-9 of 9

Last Updated: 09/26/2026